Ocular Therapeutix (OCUL) Shares are Down -3.78%

Ocular Therapeutix (OCUL) has risen sharply, recording gains of 7.68% in the past 4 weeks. However, the stock has corrected -3.78% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.26% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.31% and the 50-Day Moving Average is 8.81%.The 200 Day SMA reached 13.88%


Ocular Therapeutix (NASDAQ:OCUL): After opening at $6.8, the stock dipped to an intraday low of $6.63 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.9649 and the buying power remained strong till the end. The stock closed at $6.87 for the day, a gain of 1.63% for the day session. The total traded volume was 659,251. The stocks close on the previous trading day was $6.87.

Ocular Therapeutix (OCUL) : 3 Wall Street analysts covering Ocular Therapeutix (OCUL) believe that the average level the stock could reach for the short term is $32.33. The maximum price target given is $60 and the minimum target for short term is around $16, hence the standard deviation is calculated at $24.09.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Companys product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Companys lead product candidates are OTX-DP and OTX-TP.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.